For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Xiao-Li Feng, Dandan Yu, Mi Zhang, Xiaohong Li, Qing-Cui Zou, Wentai Ma, Jian-Bao Han, Ling Xu, Cuixian Yang, Wang Qu, Zhong-Hua Deng, Junyi Long, Yanghaopeng Long, Mingkun Li, Yong-Gang Yao, Xing-Qi Dong, Jianxiong Zeng, Ming-Hua Li. Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates [J].VIROLOGICA SINICA, 2022, 37(6) : 804-812.  http://dx.doi.org/10.1016/j.virs.2022.09.007

Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates

  • The continuously arising of SARS-CoV-2 variants has been posting a great threat to public health safety globally, from B.1.17 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) to B.1.1.529 (Omicron). The emerging or reemerging of the SARS-CoV-2 variants of concern is calling for the constant monitoring of their epidemics, pathogenicity and immune escape. In this study, we aimed to characterize replication and pathogenicity of the Alpha and Delta variant strains isolated from patients infected in Laos. The amino acid mutations within the spike fragment of the isolates were determined via sequencing. The more efficient replication of the Alpha and Delta isolates was documented than the prototyped SARS-CoV-2 in Calu-3 and Caco-2 cells, while such features were not observed in Huh-7, Vero E6 and HPA-3 cells. We utilized both animal models of human ACE2 (hACE2) transgenic mice and hamsters to evaluate the pathogenesis of the isolates. The Alpha and Delta can replicate well in multiple organs and cause moderate to severe lung pathology in these animals. In conclusion, the spike protein of the isolated Alpha and Delta variant strains was characterized, and the replication and pathogenicity of the strains in the cells and animal models were also evaluated.

  • 加载中
  • 10.1016j.virs.2022.09.007-ESM.docx
    1. Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O'connell, A.M., Simons, D., Blomquist, P.B., Zaidi, A., Nash, S., Aziz, N.I.B.A., Thelwall, S., Dabrera, G., Myers, R., Amirthalingam, G., Gharbia, S., Barrett, J.C., Elson, R., Ladhani, S.N., Ferguson, N., Zambon, M., Campbell, C.N.J., Brown, K., Hopkins, S., Chand, M., Ramsay, M., Bernal, J.L., 2022. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 2, NEJMoa2119451.

    2. Bayarri-Olmos, R., Johnsen, L.B., Idorn, M., Reinert, L.S., Rosbjerg, A., Vang, S., Hansen, C.B., Helgstrand, C., Bjelke, J.R., Bak-Thomsen, T., Paludan, S.R., Garred, P., Skjoedt, M.O., 2021. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. Elife 10, e70002.

    3. Bernal, J.L., Gower, C., Andrews, N., 2021. Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant. N. Engl. J. Med. 385, e92.

    4. Castiglione, G.M., Zhou, L.L., Xu, Z.H., Neiman, Z., Hung, C.F., Duh, E.J., 2021. Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2. PLoS Biol. 19, e3001510.

    5. Charmet, T., Schaeffer, L., Grant, R., Galmiche, S., Cheny, O., Von Platen, C., Maurizot, A., Rogoff, A., Omar, F., David, C., Septfons, A., Cauchemez, S., Gaymard, A., Lina, B., Lefrancois, L.H., Enouf, V., van der Werf, S., Mailles, A., Levy-Bruhl, D., Carrat, F., Fontanet, A., 2021. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: results from a nationwide case-control study in France. Lancet Reg Health Eur 8, 100171.

    6. Chen, J., Wei, G.W., 2022. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. Res Sq 3, rs-1362445.

    7. da Silva, J.C., Felix, V.B., Leao, S., Trindade-Filho, E.M., Scorza, F.A., 2021. New Brazilian variant of the SARS-CoV-2 (P1/Gamma) of COVID-19 in Alagoas state. Braz. J. Infect. Dis. 25, 101588.

    8. Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M.A., Hernan, M.A., Lipsitch, M., Reis, B., Balicer, R.D., 2021. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412-1423.

    9. de Souza, G.A.P., Le Bideau, M., Boschi, C., Ferreira, L., Wurtz, N., Devaux, C., Colson, P., La Scola, B., 2022. Emerging SARS-CoV-2 genotypes show different replication patterns in human pulmonary and intestinal epithelial cells. VirusesBasel 14, 23.

    10. Deng, X.D., Garcia-Knight, M.A., Khalid, M.M., Servellita, V., Wang, C.D.C., Morris, M.K., Sotomayor-Gonzalez, A., Glasner, D.R., Reyes, K.R., Gliwa, A.S., Reddy, N.P., San Martin, C.S., Federman, S., Cheng, J., Balcerek, J., Taylor, J., Streithorst, J.A., Miller, S., Sreekumar, B., Chen, P.Y., Schulze-Gahmen, U., Taha, T.Y., Hayashi, J.M., Simoneau, C.R., Kumar, G.R., McMahon, S., Lidsky, P.V., Xiao, Y.H., Hemarajata, P., Green, N.M., Espinosa, A., Kath, C., Haw, M., Bell, J., Hacker, J.K., Hanson, C., Wadford, D.A., Anaya, C., Ferguson, D., Frankino, P.A., Shivram, H., Lareau, L.F., Wyman, S.K., Ott, M., Andino, R., Chiu, C.Y., 2021. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426-3437.

    11. Greaney, A.J., Loes, A.N., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y., Bloom, J.D., 2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463-476.

    12. Grint, D.J., Wing, K., Houlihan, C., Gibbs, H.P., Evans, S.J.W., Williamson, E., McDonald, H.I., Bhaskaran, K., Evans, D., Walker, A.J., Hickman, G., Nightingale, E., Schultze, A., Rentsch, C.T., Bates, C., Cockburn, J., Curtis, H.J., Morton, C.E., Bacon, S., Davy, S., Wong, A.Y.S., Mehrkar, A., Tomlinson, L., Douglas, I.J., Mathur, R., MacKenna, B., Ingelsby, P., Croker, R., Parry, J., Hester, F., Harper, S., DeVito, N.J., Hulme, W., Tazare, J., Smeeth, L., Goldacre, B., Eggo, R.M., 2021. Severity of SARS-CoV-2 alpha variant (B.1.1.7) in England. Clin. Infect. Dis. 6, ciab754.

    13. Hall, V.J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., Islam, J., Karagiannis, I., Munro, K., Khawam, J., Chand, M.A., Brown, C.S., Ramsay, M., Lopez-Bernal, J., Hopkins, S., Group, S.S., 2021. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397, 1725-1735.

    14. Han, P.C., Li, L.J., Liu, S., Wang, Q.S., Zhang, D., Xu, Z.P., Han, P., Li, X.M., Peng, Q., Su, C., Huang, B.H., Li, D.D., Zhang, R., Tian, M.X., Fu, L.T., Gao, Y.Z., Zhao, X., Liu, K.F., Qi, J.X., Gao, G.F., Wang, P.Y., 2022. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell 185, 630-640.

    15. Harvey, W.T., Carabelli, A.M., Jackson, B., Gupta, R.K., Thomson, E.C., Harrison, E.M., Ludden, C., Reeve, R., Rambaut, A., Consortium, C.-G.U., Peacock, S.J., Robertson, D.L., 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409-424.

    16. Hitchings, M.D.T., Ranzani, O.T., Dorion, M., D'Agostini, T.L., de Paula, R.C., de Paula, O.F.P., Villela, E.F.D., Torres, M.S.S., de Oliveira, S.B., Schulz, W., Almiron, M., Said, R., de Oliveira, R.D., Silva, P.V., de Araujo, W.N., Gorinchteyn, J.C., Andrews, J.R., Cummings, D.A.T., Ko, A.I., Croda, J., 2021. Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in Sao Paulo. Nat. Commun. 12, 6220.

    17. Katoh, K., Standley, D.M., 2013. MAFFT multiple sequence alignment software version 7:improvements in performance and usability. Mol. Biol. Evol. 30, 772-780.

    18. Kraemer, M.U.G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J.T., Baele, G., Parag, K.V., Battle, A.L., Gutierrez, B., Jackson, B., Colquhoun, R., O'Toole, A., Klein, B., Vespignani, A., Volz, E., Faria, N.R., Aanensen, D.M., Loman, N.J., du Plessis, L., Cauchemez, S., Rambaut, A., Scarpino, S.V., Pybus, O.G., Consor, C.-G.U.C.-U., 2021. Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science 373, 889-895.

    19. Kumar, S., Karuppanan, K., Subramaniam, G., 2022. Omicron (BA.1) and sub-variants(BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: a comparative sequence and structural-based computational assessment. J. Med. Virol. 94, 4780-4791.

    20. Li, H., 2018. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094-3100.

    21. Lin, S., Chen, Z.M., Zhang, X.D., Wen, A.O., Yuan, X., Yu, C.Z., Yang, J., He, B., Cao, Y., Lu, G.W., 2022. Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding. Signal Transduct. Targeted Ther. 7, 56.

    22. Liu, C., Zhou, D., Nutalai, R., Duyvesteyn, H.M.E., Tuekprakhon, A., Ginn, H.M., Dejnirattisai, W., Supasa, P., Mentzer, A.J., Wang, B., Case, J.B., Zhao, Y., Skelly, D.T., Chen, R.E., Johnson, S.A., Ritter, T.G., Mason, C., Malik, T., Temperton, N., Paterson, N.G., Williams, M.A., Hall, D.R., Clare, D.K., Howe, A., Goulder, P.J.R., Fry, E.E., Diamond, M.S., Mongkolsapaya, J., Ren, J., Stuart, D.I., Screaton, G.R., 2022a. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host Microbe 30, 53-68.

    23. Liu, Y., Liu, J., Plante, K.S., Plante, J.A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., Widen, S.G., Menachery, V.D., Shi, P.Y., Weaver, S.C., 2022b. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294-299.

    24. Lubinski, B., Fernandes, M.H.V., Frazier, L., Tang, T., Daniel, S., Diel, D.G., Jaimes, J.A., Whittaker, G.R., 2022. Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. iScience 25, 103589.

    25. Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., Padayachee, S.D., Dheda, K., Barnabas, S.L., Bhorat, Q.E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha, S., Bhiman, J.N., Bhorat, A.E., du Plessis, J., Esmail, A., Groenewald, M., Horne, E., Hwa, S.H., Jose, A., Lambe, T., Laubscher, M., Malahleha, M., Masenya, M., Masilela, M., McKenzie, S., Molapo, K., Moultrie, A., Oelofse, S., Patel, F., Pillay, S., Rhead, S., Rodel, H., Rossouw, L., Taoushanis, C., Tegally, H., Thombrayil, A., van Eck, S., Wibmer, C.K., Durham, N.M., Kelly, E.J., Villafana, T.L., Gilbert, S., Pollard, A.J., de Oliveira, T., Moore, P.L., Sigal, A., Izu, A., Group, N.-S., Wits, V.C.G., 2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885-1898.

    26. Moyo-Gwete, T., Madzivhandila, M., Mkhize, N.N., Kgagudi, P., Ayres, F., Lambson, B.E., Manamela, N.P., Richardson, S.I., Makhado, Z., van der Mescht, M.A., de Beer, Z., de Villiers, T.R., Burgers, W.A., Ntusi, N.A.B., Rossouw, T., Ueckermann, V., Boswell, M.T., Moore, P.L., 2022. Shared N417-dependent epitope on the SARS-CoV-2 omicron, beta, and delta plus variants. J. Virol. 96, e0055822.

    27. Muik, A., Lui, B.G., Wallisch, A.K., Bacher, M., Muhl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Garcia, R.D.G., Poran, A., Shpyro, S., Finlayson, A., Cai, H., Yang, Q., Swanson, K.A., Tureci, O., Sahin, U., 2022. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678-680.

    28. Nguyen, L.T., Schmidt, H.A., von Haeseler, A., Minh, B.Q., 2015. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268-274.

    29. Patone, M., Thomas, K., Hatch, R., San Tan, P., Coupland, C., Liao, W.Q., Mouncey, P., Harrison, D., Rowan, K., Horby, P., Watkinson, P., Hippisley-Cox, J., 2021. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect. Dis. 21, 1518-1528.

    30. Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., Courtellemont, L., Pere, H., Hocqueloux, L., Fafi-Kremer, S., Prazuck, T., Mouquet, H., Bruel, T., Simon-Loriere, E., Rey, F.A., Schwartz, O., 2021. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276-280.

    31. Radvak, P., Kwon, H.J., Kosikova, M., Ortega-Rodriguez, U., Xiang, R.X., Phue, J.N., Shen, R.F., Rozzelle, J., Kapoor, N., Rabara, T., Fairman, J., Xie, H., 2021. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat. Commun. 12, 6559.

    32. Rajah, M.M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Dufloo, J., Gellenoncourt, S., Bongers, A., Zivaljic, M., Planchais, C., GuivelBenhassine, F., Porrot, F., Mouquet, H., Chakrabarti, L.A., Buchrieser, J., Schwartz, O., 2021. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. EMBO J. 40, e108944.

    33. Reed, L.J., Muench, H., 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.

    34. Sadoff, J., Gray, G., Vandebosch, A., Cardenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K.L., Robb, M.L., Treanor, J., Barouch, D.H., Stoddard, J., Ryser, M.F., Marovich, M.A., Neuzil, K.M., Corey, L., Cauwenberghs, N., Tanner, T., Hardt, K., Ruiz-Guinazu, J., Le Gars, M., Schuitemaker, H., Van Hoof, J., Struyf, F., Douoguih, M., Group, E.S., 2021. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187-2201.

    35. Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K., Sadamasu, K., Kimura, I., Ito, J., Wu, J.Q., Iwatsuki-Horimoto, K., Ito, M., Yamayoshi, S., Loeber, S., Tsuda, M., Wang, L., Ozono, S., Butlertanaka, E.P., Tanaka, Y.L., Shimizu, R., Shimizu, K., Yoshimatsu, K., Kawabata, R., Sakaguchi, T., Tokunaga, K., Yoshida, I., Asakura, H., Nagashima, M., Kazuma, Y., Nomura, R., Horisawa, Y., Yoshimura, K., Takaori-Kondo, A., Imai, M., Tanaka, S., Nakagawa, S., Ikeda, T., Fukuhara, T., Kawaoka, Y., Sato, K., G2P-Japan, G.P.J., 2022. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300-306.

    36. Sasaki, M., Uemura, K., Sato, A., Toba, S., Sanaki, T., 2021. SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 17, e1009233.

    37. Sheikh, A., Robertson, C., Taylor, B., 2021. BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant. N. Engl. J. Med. 385, 2195-2197.

    38. Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M.S.L., Moodley, D., Hanley, S., Fouche, L., Louw, C., Tameris, M., Singh, N., Goga, A., Dheda, K., Grobbelaar, C., Kruger, G., Carrim-Ganey, N., Baillie, V., de Oliveira, T., Lombard Koen, A., Lombaard, J.J., Mngqibisa, R., Bhorat, A.E., Benade, G., Lalloo, N., Pitsi, A., Vollgraaff, P.L., Luabeya, A., Esmail, A., Petrick, F.G., Oommen-Jose, A., Foulkes, S., Ahmed, K., Thombrayil, A., Fries, L., Cloney-Clark, S., Zhu, M., Bennett, C., Albert, G., Faust, E., Plested, J.S., Robertson, A., Neal, S., Cho, I., Glenn, G.M., Dubovsky, F., Madhi, S.A., nCo, V.S.G., 2021. Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1899-1909.

    39. Shu, C.J., Huang, X., Tang, H.H., Mo, D.D., Zhou, J.W., Deng, C., 2021. Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. Zool. Res. 42, 170-181.

    40. Shuai, H., Chan, J.F., Hu, B., Chai, Y., Yuen, T.T., Yin, F., Huang, X., Yoon, C., Hu, J.C., Liu, H., Shi, J., Liu, Y., Zhu, T., Zhang, J., Hou, Y., Wang, Y., Lu, L., Cai, J.P., Zhang, A.J., Zhou, J., Yuan, S., Brindley, M.A., Zhang, B.Z., Huang, J.D., To, K.K., Yuen, K.Y., Chu, H., 2022. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693-699.

    41. Singh, J., Rahman, S.A., Ehtesham, N.Z., Hira, S., Hasnain, S.E., 2021. SARS-CoV-2 variants of concern are emerging in India. Nat. Med. 27, 1131-1133.

    42. Song, T.Z., Zheng, H.Y., Han, J.B., Jin, L., Yang, X., Liu, F.L., Luo, R.H., Tian, R.R., Cai, H.R., Feng, X.L., Liu, C., Li, M.H., Zheng, Y.T., 2020. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zool. Res. 41, 503-516.

    43. Tang, P., Hasan, M.R., Chemaitelly, H., Yassine, H.M., Benslimane, F.M., Al Khatib, H.A., AlMukdad, S., Coyle, P., Ayoub, H.H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A.H., Latif, A.N., Shaik, R.M., Rahim, H.F.A., Nasrallah, G.K., Al Kuwari, M.G., Al Romaihi, H.E., Butt, A.A., Al-Thani, M.H., Al Khal, A., Bertollini, R., Abu-Raddad, L.J., 2021. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat. Med. 27, 2136-2143.

    44. Tao, K., Tzou, P.L., Nouhin, J., Gupta, R.K., de Oliveira, T., Kosakovsky Pond, S.L., Fera, D., Shafer, R.W., 2021. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757-773.

    45. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A., Mohale, T., Glass, A.J., Engelbrecht, S., Van Zyl, G., Preiser, W., Petruccione, F., Sigal, A., Hardie, D., Marais, G., Hsiao, N.Y., Korsman, S., Davies, M.A., Tyers, L., Mudau, I., York, D., Maslo, C., Goedhals, D., Abrahams, S., Laguda-Akingba, O., Alisoltani-Dehkordi, A., Godzik, A., Wibmer, C.K., Sewell, B.T., Lourenco, J., Alcantara, L.C.J., Kosakovsky Pond, S.L., Weaver, S., Martin, D., Lessells, R.J., Bhiman, J.N., Williamson, C., de Oliveira, T., 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438-443.

    46. van Loon, W., Rossig, H., Burock, S., Hofmann, J., Bernhard, J., Linzbach, E., Pettenkofer, D., Schonfeld, C., Gertler, M., Seybold, J., Kurth, T., Mockenhaupt, F.P., 2021. Emergence of SARS-CoV-2 B.1.1.7 lineage at outpatient testing site, Berlin, Germany , January March 2021. Emerg. Infect. Dis. 27, 1931-1934.

    47. Wang, Y.D., Ma, Y.P., Xu, Y., Liu, J.Y., Li, X., Chen, Y.Y., Chen, Y., Xie, J., Xiao, L.B., Xiang, Z., Wu, F., Huang, J.H., 2022. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma. Emerg. Microb. Infect. 11, 424-427.

    48. Xie, X.C., Han, J.B., Ma, G.Q., Feng, X.L., Li, X.H., Zou, Q.C., Deng, Z.H., Zeng, J.X., 2021. Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool. Res. 42, 789-791.

    49. Xu, L., Yu, D.D., Ma, Y.H., Yao, Y.L., Luo, R.H., Feng, X.L., Cai, H.R., Han, J.B., Wang, X.H., Li, M.H., Ke, C.W., Zheng, Y.T., Yao, Y.G., 2020. COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. Zool. Res. 41, 517-526.

    50. Zeng, J., Dong, S., Luo, Z., Xie, X., Fu, B., Li, P., Liu, C., Yang, X., Chen, Y., Wang, X., Liu, Z., Wu, J., Yan, Y., Wang, F., Chen, J.F., Zhang, J., Long, G., Goldman, S.A., Li, S., Zhao, Z., Liang, Q., 2020. The zika virus capsid disrupts corticogenesis by suppressing Dicer activity and miRNA biogenesis. Cell Stem Cell 27, 618-632.e9.

    51. Zeng, J., Wang, Y., Luo, Z., Chang, L.C., Yoo, J.S., Yan, H., Choi, Y., Xie, X., Deverman, B.E., Gradinaru, V., Gupton, S.L., Zlokovic, B.V., Zhao, Z., Jung, J.U., 2019. TRIM9-mediated resolution of neuroinflammation confers neuroprotection upon ischemic stroke in mice. Cell Rep. 27, 549-560 e6.

    52. Zeng, J., Xie, X., Feng, X.L., Xu, L., Han, J.B., Yu, D., Zou, Q.C., Liu, Q., Li, X., Ma, G., Li, M.H., Yao, Y.G., 2022. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice. EBioMedicine 75, 103803.

    53. Zhang, H., Deng, S.S., Ren, L.T., Zheng, P.Y., Hu, X.W., Jin, T.C., Tan, X., 2021. Profiling CD8(+) T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Rep. 36, 109708.

    54. Zhang, L.Z., Jackson, C.B., Mou, H.H., Ojha, A., Peng, H.Y., Quinlan, B.D., Rangarajan, E.S., Pan, A.D., Vanderheiden, A., Suthar, M.S., Li, W.H., Izard, T., Rader, C., Farzan, M., Choe, H., 2020. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013.

    55. Zhao, H.J., Lu, L., Peng, Z., Chen, L.L., Meng, X.J., Zhang, C.Y., Ip, J.D., Chan, W.M., Chu, A.W.H., Chan, W.H., Jin, D.Y., Chen, H.L., Yuen, W.Y., To, K.K.W., 2022. SARSCoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microb. Infect. 11, 277-283.

  • 加载中

Article Metrics

Article views(296) PDF downloads(9) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates

      Corresponding author: Xing-Qi Dong, dongxq8001@126.com
      Corresponding author: Jianxiong Zeng, zengjianxiong@mail.kiz.ac.cn
      Corresponding author: Ming-Hua Li, limh@mail.kiz.ac.cn
    • a Kunming National High-level Biosafety Research Center for Non-Human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650107, China;
    • b Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650201, China;
    • c Department of Infectious Diseases, Yunnan Provincial Infectious Diseases Hospital, Kunming, 650301, China;
    • d Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, and China National Center for Bioinformation, Beijing, 100101, China;
    • e Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, 650201, China;
    • f National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650107, China;
    • g Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, 650204, China;
    • h Yunnan Key Laboratory of Biodiversity Information, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650201, China;
    • i University of Chinese Academy of Sciences, Beijing, 100049, China

    Abstract: The continuously arising of SARS-CoV-2 variants has been posting a great threat to public health safety globally, from B.1.17 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) to B.1.1.529 (Omicron). The emerging or reemerging of the SARS-CoV-2 variants of concern is calling for the constant monitoring of their epidemics, pathogenicity and immune escape. In this study, we aimed to characterize replication and pathogenicity of the Alpha and Delta variant strains isolated from patients infected in Laos. The amino acid mutations within the spike fragment of the isolates were determined via sequencing. The more efficient replication of the Alpha and Delta isolates was documented than the prototyped SARS-CoV-2 in Calu-3 and Caco-2 cells, while such features were not observed in Huh-7, Vero E6 and HPA-3 cells. We utilized both animal models of human ACE2 (hACE2) transgenic mice and hamsters to evaluate the pathogenesis of the isolates. The Alpha and Delta can replicate well in multiple organs and cause moderate to severe lung pathology in these animals. In conclusion, the spike protein of the isolated Alpha and Delta variant strains was characterized, and the replication and pathogenicity of the strains in the cells and animal models were also evaluated.

    Reference (55) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return